Fifth Third Bancorp (FITB)
Fifth Third Bancorp is a diversified financial services company headquartered in Cincinnati, Ohio. Fifth Third operates four main businesses: Commercial Banking, Branch Banking, Consumer Lending, and Wealth & Asset Management. Fifth Third also has an 8.6% interest in Vantiv Holding, LLC.
Fifth Third Bancorp (FITB)‘s Financial Overview
Fifth Third Bancorp (FITB) surged 0.7% yesterday to close its trading session at $31.56. The company has 1 year Price Target of $34.25. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 6.96 Million shares yesterday. The firm shows the market capitalization of $23.18 Billion.
Fifth Third Bancorp (FITB) reported its last quarterly earnings on 12/30/2017 where the firm reported its Actual EPS of $0.48/share.
The firm is trading with SMA20 of -4.96 Percent, SMA50 of SMA50 Percent and SMA200 of 8.49 percent. Fifth Third Bancorp has P/S value of 5.16 while its P/B value stands at 1.48. Similarly, the company has Return on Assets of 1.5 percent, Return on Equity of 13.9 percent and Return on Investment of 9.2 Percent.
The Stock currently has Analyst’ mean Recommendation of 3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 26 analysts offering 12-month price forecasts for Fifth Third Bancorp have a median target of 34.00, with a high estimate of 37.25 and a low estimate of 29.00. The median estimate represents a +7.73% increase from the last price of 31.56.
Johnson & Johnson (JNJ)
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women’s health fields, nutritional and over-the-counter pharmaceutical products. The company’s Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women’s health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Johnson & Johnson (JNJ)‘s Financial Outlook
The 22 analysts offering 12-month price forecasts for Johnson & Johnson have a median target of 152.50, with a high estimate of 175.00 and a low estimate of 110.00. The median estimate represents a +19.65% increase from the last price of 127.45.
According to Zacks Investment Research, Johnson & Johnson has a Consensus Recommendation of 2.22. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged0.19% and closed its last trading session at $127.45. The company has the market capitalization of $348.13 Billion. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 6.87 Million shares. The company has a total of 2.73 Billion shares outstanding.
The company has YTD performance of -8.78 percent. Beta for Johnson & Johnson stands at 0.75 while its ATR (average true range) is 2.61. The company has Weekly Volatility of 2.12%% and Monthly Volatility of 1.98%.
Johnson & Johnson has distance from 20-day Simple Moving Average (SMA20) of -2.14%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of -6.03%.
The Company currently has ROA (Return on Assets) of 0.9 percent, Return on Equity (ROE) of 1.9 Percent and Return on Investment (ROI) of 15.7% with Gross margin of 67 percent and Operating & Profit margin of 23.1% and 1.7% respectively.